166 related articles for article (PubMed ID: 21928064)
1. Osteopenia in children with cerebral palsy can be treated with oral alendronate.
Paksu MS; Vurucu S; Karaoglu A; Karacalioglu AO; Polat A; Yesilyurt O; Unay B; Akin R
Childs Nerv Syst; 2012 Feb; 28(2):283-6. PubMed ID: 21928064
[TBL] [Abstract][Full Text] [Related]
2. Alendronate for steroid-induced osteopenia in children with acute lymphoblastic leukaemia or non-Hodgkin's lymphoma: results of a pilot study.
Wiernikowski JT; Barr RD; Webber C; Guo CY; Wright M; Atkinson SA
J Oncol Pharm Pract; 2005 Jun; 11(2):51-6. PubMed ID: 16460605
[TBL] [Abstract][Full Text] [Related]
3. Alendronate, vitamin D, and calcium for the treatment of osteopenia/osteoporosis associated with HIV infection.
Mondy K; Powderly WG; Claxton SA; Yarasheski KH; Royal M; Stoneman JS; Hoffmann ME; Tebas P
J Acquir Immune Defic Syndr; 2005 Apr; 38(4):426-31. PubMed ID: 15764959
[TBL] [Abstract][Full Text] [Related]
4. Are oral bisphosphonates effective in improving lumbar bone mineral density in breast cancer survivors with osteopenia or osteoporosis?
Sawka AM; Ioannidis G; Papaioannou A; Thabane L; Olszynski WP; Brown JP; Hanley DA; Murray TM; Josse RG; Sebaldt RJ; Petrie A; Tenenhouse A; Goldsmith CH; Boulos P; Kouroukis T; Adachi JD
J Obstet Gynaecol Can; 2005 Aug; 27(8):759-64. PubMed ID: 16287007
[TBL] [Abstract][Full Text] [Related]
5. Alendronate in combination with calcium and vitamin D prevents bone loss after orthotopic liver transplantation: a prospective single-center study.
Millonig G; Graziadei IW; Eichler D; Pfeiffer KP; Finkenstedt G; Muehllechner P; Koenigsrainer A; Margreiter R; Vogel W
Liver Transpl; 2005 Aug; 11(8):960-6. PubMed ID: 16035083
[TBL] [Abstract][Full Text] [Related]
6. Alendronate improves vitamin D-resistant osteopenia triggered by gastrectomy in patients with gastric cancer followed long term.
Suzuki Y; Ishibashi Y; Omura N; Kawasaki N; Kashiwagi H; Yanaga K; Abo M; Urashima M
J Gastrointest Surg; 2005; 9(7):955-60. PubMed ID: 16137591
[TBL] [Abstract][Full Text] [Related]
7. Bone loss after heart transplant: effect of alendronate, etidronate, calcitonin, and calcium plus vitamin D3.
Gilfraguas L; Guadalix S; Martinez G; Jodar E; Vara J; Gomez-Sanchez MA; Delgado J; De La Cruz J; Lora D; Hawkins F
Prog Transplant; 2012 Sep; 22(3):237-43. PubMed ID: 22951500
[TBL] [Abstract][Full Text] [Related]
8. Experience with alendronate treatment for 7 years among Japanese men with osteoporosis or osteopenia and clinical risk factors for fractures.
Iwamoto J; Uzawa M
Clin Rheumatol; 2016 Jan; 35(1):205-12. PubMed ID: 25367347
[TBL] [Abstract][Full Text] [Related]
9. Effect of low-dose alendronate treatment on bone mineral density and bone turnover markers in Chinese postmenopausal women with osteopenia and osteoporosis.
Li M; Zhang ZL; Liao EY; Chen DC; Liu J; Tao TZ; Wu W; Xia WB; Lu YJ; Sheng ZF; Lu CY; Meng GL; Xu L; Zhang WJ; Hu YY; Xu L
Menopause; 2013 Jan; 20(1):72-8. PubMed ID: 22968256
[TBL] [Abstract][Full Text] [Related]
10. Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIV.
McComsey GA; Kendall MA; Tebas P; Swindells S; Hogg E; Alston-Smith B; Suckow C; Gopalakrishnan G; Benson C; Wohl DA
AIDS; 2007 Nov; 21(18):2473-82. PubMed ID: 18025884
[TBL] [Abstract][Full Text] [Related]
11. Bisphosphonate use in children with cerebral palsy.
Hurley T; Zareen Z; Stewart P; McDonnell C; McDonald D; Molloy E
Cochrane Database Syst Rev; 2021 Jul; 7(7):CD012756. PubMed ID: 34224134
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the effects of alendronate and alfacalcidol on hip bone mineral density and bone turnover in Japanese men having osteoporosis or osteopenia with clinical risk factors for fractures.
Iwamoto J; Sato Y; Uzawa M; Takeda T; Matsumoto H
Yonsei Med J; 2009 Aug; 50(4):474-81. PubMed ID: 19718394
[TBL] [Abstract][Full Text] [Related]
13. Interventions for the treatment of decreased bone mineral density associated with HIV infection.
Lin D; Rieder MJ
Cochrane Database Syst Rev; 2007 Apr; (2):CD005645. PubMed ID: 17443607
[TBL] [Abstract][Full Text] [Related]
14. Treatment of low bone density in young people with cystic fibrosis: a multicentre, prospective, open-label observational study of calcium and calcifediol followed by a randomised placebo-controlled trial of alendronate.
Bianchi ML; Colombo C; Assael BM; Dubini A; Lombardo M; Quattrucci S; Bella S; Collura M; Messore B; Raia V; Poli F; Bini R; Albanese CV; De Rose V; Costantini D; Romano G; Pustorino E; Magazzù G; Bertasi S; Lucidi V; Traverso G; Coruzzo A; Grzejdziak AD
Lancet Respir Med; 2013 Jul; 1(5):377-85. PubMed ID: 24429202
[TBL] [Abstract][Full Text] [Related]
15. Positive effect of alendronate on bone mineral density and markers of bone turnover in patients with rheumatoid arthritis on chronic treatment with low-dose prednisone: a randomized, double-blind, placebo-controlled trial.
Lems WF; Lodder MC; Lips P; Bijlsma JW; Geusens P; Schrameijer N; van de Ven CM; Dijkmans BA
Osteoporos Int; 2006; 17(5):716-23. PubMed ID: 16463007
[TBL] [Abstract][Full Text] [Related]
16. Alendronate decreases the fracture risk in patients with prostate cancer on androgen-deprivation therapy and with severe osteopenia or osteoporosis.
Planas J; Trilla E; Raventós C; Cecchini L; Orsola A; Salvador C; Placer J; Encabo G; Morote J
BJU Int; 2009 Dec; 104(11):1637-40. PubMed ID: 19549260
[TBL] [Abstract][Full Text] [Related]
17. Fall Prevention and Anti-Osteoporosis in Osteopenia Patients of 80 Years of Age and Older: A Randomized Controlled Study.
Zhou J; Liu B; Qin MZ; Liu JP
Orthop Surg; 2020 Jun; 12(3):890-899. PubMed ID: 32495521
[TBL] [Abstract][Full Text] [Related]
18. Increase in bone mass after correction of vitamin D insufficiency in bisphosphonate-treated patients.
Geller JL; Hu B; Reed S; Mirocha J; Adams JS
Endocr Pract; 2008 Apr; 14(3):293-7. PubMed ID: 18463035
[TBL] [Abstract][Full Text] [Related]
19. [Clinical application of alendronate for osteoporosis/osteopenia secondary to hyperthyroidism].
Yang LJ; Shen FX; Zheng JC; Zhang HL
Zhongguo Gu Shang; 2012 Feb; 25(2):133-7. PubMed ID: 22577718
[TBL] [Abstract][Full Text] [Related]
20. Bisphosphonate therapy for reduced bone mineral density during treatment of acute lymphoblastic leukemia in childhood and adolescence: a report of preliminary experience.
Lethaby C; Wiernikowski J; Sala A; Naronha M; Webber C; Barr RD
J Pediatr Hematol Oncol; 2007 Sep; 29(9):613-6. PubMed ID: 17805035
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
